Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Cassava Sciences stock price, quote, forecast and news

SAVA
US14817C1071
A2PGL8

Price

12.33
Today +/-
+0
Today %
+0 %
P

Cassava Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cassava Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cassava Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cassava Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cassava Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cassava Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cassava Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cassava Sciences’s growth potential.

Cassava Sciences Revenue, EBIT and net profit per share

DateCassava Sciences RevenueCassava Sciences EBITCassava Sciences Net Income
2028e73.85 M undefined-34.48 M undefined0 undefined
2027e6.53 M undefined-107.92 M undefined-91.52 M undefined
2026e0 undefined-121.99 M undefined-58.73 M undefined
2025e102 M undefined-20.66 M undefined17.62 M undefined
2024e0 undefined-90.22 M undefined-38.17 M undefined
20230 undefined-105.96 M undefined-97.22 M undefined
20220 undefined-80.02 M undefined-76.25 M undefined
20210 undefined-32.87 M undefined-32.39 M undefined
20200 undefined-6.8 M undefined-6.33 M undefined
20190 undefined-4.96 M undefined-4.63 M undefined
20180 undefined-6.66 M undefined-6.56 M undefined
20170 undefined-11.95 M undefined-11.91 M undefined
20160 undefined-14.96 M undefined-14.85 M undefined
20150 undefined-14.2 M undefined-14.15 M undefined
20140 undefined-12.43 M undefined-12.39 M undefined
201341.12 M undefined31.37 M undefined31.54 M undefined
201210.89 M undefined-3.9 M undefined-3.45 M undefined
201111.48 M undefined-3.51 M undefined-2.61 M undefined
201016.81 M undefined-13.7 M undefined-12.02 M undefined
200920.56 M undefined-6.75 M undefined-3.47 M undefined
200863.73 M undefined8.71 M undefined15.35 M undefined
200765.98 M undefined10.17 M undefined20.31 M undefined
200653.92 M undefined-550,000 undefined6.19 M undefined
20055.08 M undefined-32.72 M undefined-30.67 M undefined
20040 undefined-38.96 M undefined-37.78 M undefined

Cassava Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
000000055365632016111041000000000001020673
--------960.0022.64-3.08-68.25-20.00-31.25-9.09310.00--------------1,116.67
-------------------------------
0000000000000000000000000000000
0-4-20-17-16-22-38-320108-6-13-3-331-12-14-14-11-6-4-6-32-80-105-90-20-121-107-34
--------640.00-15.3812.70-30.00-81.25-27.27-30.0075.61------------19.61--1,783.33-46.58
0-4-31-14-15-21-37-3062015-3-12-2-331-12-14-14-11-6-4-6-32-76-97-3817-58-910
--675.00-54.847.1440.0076.19-18.92-120.00233.33-25.00-120.00300.00-83.3350.00-1,133.33-138.7116.67--21.43-45.45-33.3350.00433.33137.5027.63-60.82-144.74-441.1856.90-
0.140.481.953.623.864.215.326.266.56.536.276.026.096.316.396.466.476.546.526.5410.6817.4126.1139.4140.241.9300000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Cassava Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cassava Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cassava Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cassava Sciences's financial health and stability.

Assets

Cassava Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cassava Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cassava Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cassava Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0-4-17-14-15-21-37-3062015-3-12-2-331-12-14-14-11-6-4-6-32-76-97
0000000000000000000000001,0001,000
00000000000000000000000000
00100041433-2-1-4160001-100000-49
01810000-21-16703012-347685421349
00000000000000000000000000
000000000201-30000000000000
0-2-7-12-15-20-32113-11211-1400-7-6-9-9-12-8-4-2-5-30-77-82
00-1-10000000000000000000-22-20
00-1-10-65-32-19-696980-103525917510-22000-22-20
00000-65-32-18-696980-103525917510-22000000
00000000000000000000000000
00000000000000000000000000
297800475401-1-2502900000014575192472
297800475401-1-240-838-340000014575192472
-------------85.00--33.00-----------
00000000000000000000000000
2769-13-15-38-1094-797066-117-3068-230-7-9-14-69370139-32-79
-0.3-2.7-8.7-14-15.5-20.5-32.8112.7-11.91.511.2-14.7-0.1-0.3-7.2-6.9-9.6-9.3-12.3-8.2-4.8-2.5-5.4-52.4-80.2-82.44
00000000000000000000000000

Cassava Sciences stock margins

The Cassava Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cassava Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cassava Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cassava Sciences's sales revenue. A higher gross margin percentage indicates that the Cassava Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cassava Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cassava Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cassava Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cassava Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cassava Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cassava Sciences Margin History

Cassava Sciences Gross marginCassava Sciences Profit marginCassava Sciences EBIT marginCassava Sciences Profit margin
2028e0 %-46.69 %0 %
2027e0 %-1,653.13 %-1,401.92 %
2026e0 %0 %0 %
2025e0 %-20.25 %17.27 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %76.29 %76.7 %
20120 %-35.81 %-31.68 %
20110 %-30.57 %-22.74 %
20100 %-81.5 %-71.51 %
20090 %-32.83 %-16.88 %
20080 %13.67 %24.09 %
20070 %15.41 %30.78 %
20060 %-1.02 %11.48 %
20050 %-644.09 %-603.74 %
20040 %0 %0 %

Cassava Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Cassava Sciences earnings per share therefore indicates how much revenue Cassava Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cassava Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cassava Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cassava Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cassava Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cassava Sciences Revenue, EBIT and net profit per share

DateCassava Sciences Sales per ShareCassava Sciences EBIT per shareCassava Sciences Earnings per Share
2028e1.54 undefined0 undefined0 undefined
2027e0.14 undefined0 undefined-1.91 undefined
2026e0 undefined0 undefined-1.22 undefined
2025e2.13 undefined0 undefined0.37 undefined
2024e0 undefined0 undefined-0.8 undefined
20230 undefined-2.53 undefined-2.32 undefined
20220 undefined-1.99 undefined-1.9 undefined
20210 undefined-0.83 undefined-0.82 undefined
20200 undefined-0.26 undefined-0.24 undefined
20190 undefined-0.28 undefined-0.27 undefined
20180 undefined-0.62 undefined-0.61 undefined
20170 undefined-1.83 undefined-1.82 undefined
20160 undefined-2.29 undefined-2.28 undefined
20150 undefined-2.17 undefined-2.16 undefined
20140 undefined-1.92 undefined-1.91 undefined
20136.37 undefined4.86 undefined4.88 undefined
20121.7 undefined-0.61 undefined-0.54 undefined
20111.82 undefined-0.56 undefined-0.41 undefined
20102.76 undefined-2.25 undefined-1.97 undefined
20093.42 undefined-1.12 undefined-0.58 undefined
200810.16 undefined1.39 undefined2.45 undefined
200710.1 undefined1.56 undefined3.11 undefined
20068.3 undefined-0.08 undefined0.95 undefined
20050.81 undefined-5.23 undefined-4.9 undefined
20040 undefined-7.32 undefined-7.1 undefined

Cassava Sciences business model

Cassava Sciences Inc. is a biotechnology company founded in 1998. Its headquarters is in Austin, Texas. The company aims to research the inflammatory causes of neurodegenerative diseases, such as Alzheimer's, and develop new treatment options and medications. Cassava Sciences' business model is based on the development and commercialization of innovative therapies through research, clinical trials, and partnerships with other companies. The company focuses on developing treatment options for Alzheimer's disease. Cassava Sciences consists of various divisions that work closely together. One focus of the company is researching and developing new medications for the treatment of Alzheimer's. The company collaborates closely with scientists to develop new treatment options. Another important aspect of Cassava Sciences is conducting clinical trials to test the effectiveness and safety of the developed medications. The company collaborates with globally renowned research institutions. One of Cassava Sciences' products is the medication PTI-125, which was developed for the treatment of Alzheimer's. The medication aims to target the inflammatory causes of the disease and slow down its progression. PTI-125 is currently in Phase IIb of clinical testing and shows promising results. In recent years, Cassava Sciences has formed several partnerships with other companies to advance research and development of new treatment options. For example, the company collaborates with Pfizer and AbbVie. The history of Cassava Sciences is marked by intensive research activity and the goal of improving the quality of life for people with Alzheimer's disease. The company's research findings have been presented at scientific conferences and received significant media attention. In summary, Cassava Sciences is an innovative biotechnology company focused on researching and developing treatment options for Alzheimer's. In addition to developing new medications, the company also conducts clinical trials and collaborates with other companies to advance research. Cassava Sciences sees itself as a pioneer in the field of Alzheimer's therapy and aims to significantly improve the quality of life for people with this condition. Cassava Sciences is one of the most popular companies on Eulerpool.com.

Cassava Sciences SWOT Analysis

Strengths

Cassava Sciences Inc has a strong portfolio of novel drug candidates. The company's lead candidate, PTI-125, has shown promising results in late-stage clinical trials. Cassava Sciences Inc holds several patents that provide a competitive advantage in the neurology market. The company has a dedicated team of experienced researchers and scientists.

Weaknesses

Cassava Sciences Inc heavily relies on the success of PTI-125 as it is currently their primary revenue driver. The company has limited financial resources and may face challenges in funding future research and development. Cassava Sciences Inc has a small market presence compared to established pharmaceutical companies. The company's dependence on a single drug candidate puts it at risk of failure or setbacks.

Opportunities

The increasing prevalence of neurological disorders presents a significant market opportunity for Cassava Sciences Inc. Expansion into international markets can provide access to a larger patient population and increase revenue potential. Collaborations with larger pharmaceutical companies can provide financial support and expertise in clinical trials. The advancements in technology and data analysis can drive innovation in clinical research and drug development.

Threats

Regulatory uncertainties and the stringent approval process pose a significant threat to Cassava Sciences Inc. Intense competition from other pharmaceutical companies with similar drug candidates may limit market share. Failure to meet clinical trial endpoints or demonstrate effectiveness can result in setbacks and loss of investor confidence. The unpredictable nature of drug development and potential side effects can impact the company's reputation and credibility.

Cassava Sciences historical P/E ratio, EBIT, and P/S ratio.

Cassava Sciences shares outstanding

The number of shares was Cassava Sciences in 2023 — This indicates how many shares 41.932 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cassava Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cassava Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cassava Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cassava Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cassava Sciences Stock splits

In Cassava Sciences's history, there have been no stock splits.

Cassava Sciences dividend history and estimates

In 2023, Cassava Sciences paid a dividend amounting to 0 USD. Dividend means that Cassava Sciences distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Cassava Sciences provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Cassava Sciences’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Cassava Sciences's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Cassava Sciences Dividend History

DateCassava Sciences Dividend
20125.25 undefined
201014 undefined

Cassava Sciences dividend payout ratio

In 2023, Cassava Sciences had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Cassava Sciences distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Cassava Sciences represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Cassava Sciences could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Cassava Sciences's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Cassava Sciences Payout Ratio History

DateCassava Sciences Payout ratio
2028e0 %
2027e0 %
2026e0 %
2025e0 %
2024e0 %
20230 %
20220 %
20210 %
20200 %
20190 %
20180 %
20170 %
20160 %
20150 %
20140 %
20130 %
2012-972.22 %
20110 %
2010-710.66 %
20090 %
20080 %
20070 %
20060 %
20050 %
20040 %
Unfortunately, there are currently no price targets and forecasts available for Cassava Sciences.

Cassava Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.47 0.58  (223.61 %)2024 Q1
12/31/2023-0.53 -0.5  (5.73 %)2023 Q4
9/30/2023-0.79 -0.61  (22.83 %)2023 Q3
6/30/2023-0.6 -0.63  (-4.69 %)2023 Q2
3/31/2023-0.57 -0.58  (-2.46 %)2023 Q1
12/31/2022-0.57 -0.47  (17.72 %)2022 Q4
9/30/2022-0.49 -0.51  (-4.7 %)2022 Q3
6/30/2022-0.44 -0.48  (-8.79 %)2022 Q2
3/31/2022-0.42 -0.44  (-3.95 %)2022 Q1
12/31/2021-0.34 -0.35  (-2.43 %)2021 Q4
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Cassava Sciences stock

Eulerpool World ESG Rating (EESG©)

28/ 100

🌱 Environment

31

👫 Social

26

🏛️ Governance

28

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cassava Sciences list of shareholders

%
Name
Stocks
Change
Date
5.69 % BlackRock Institutional Trust Company, N.A.2,728,476186,33412/31/2023
4.83 % The Vanguard Group, Inc.2,315,44253,86012/31/2023
2.79 % Barbier (Remi)1,338,157-1,150,3743/19/2024
2.67 % Robertson (Sanford R)1,280,221213,3703/19/2024
2.23 % State Street Global Advisors (US)1,069,64944,05912/31/2023
1.82 % Geode Capital Management, L.L.C.873,99643,74612/31/2023
1.21 % Gallacher Capital Management, LLC581,6063,78212/31/2023
1.04 % Cowen & Co., LLC500,000500,00012/31/2023
0.89 % Morgan Stanley Smith Barney LLC426,01970,46112/31/2023
0.78 % Jane Street Capital, L.L.C.374,206360,68612/31/2023
1
2
3
4
5
...
10

Cassava Sciences Executives and Management Board

Mr. R. Christopher Cook59
Cassava Sciences Senior Vice President, General Counsel
Compensation 3.66 M
Mr. Remi Barbier63
Cassava Sciences Chairman of the Board, President, Chief Executive Officer (since 1998)
Compensation 1.11 M
Mr. Eric Schoen54
Cassava Sciences Chief Financial Officer
Compensation 426,610
Dr. James Kupiec70
Cassava Sciences Chief Medical Officer
Compensation 400,000
Mr. Sanford Robertson91
Cassava Sciences Lead Independent Director
Compensation 75,924
1
2
3

Most common questions regarding Cassava Sciences

What values and corporate philosophy does Cassava Sciences represent?

Cassava Sciences Inc represents values of innovation, integrity, and dedication to improving the lives of patients. The company's corporate philosophy revolves around developing and commercializing therapies for Alzheimer's disease, with a strong focus on scientific rigor and patient-centric approaches. Cassava Sciences Inc is committed to conducting clinical studies, advancing research, and collaborating with experts in the field to address the urgent need for effective Alzheimer's treatments. With its cutting-edge scientific expertise and passion for making a difference, Cassava Sciences Inc strives to be a leader in the biopharmaceutical industry.

In which countries and regions is Cassava Sciences primarily present?

Cassava Sciences Inc is primarily present in the United States of America.

What significant milestones has the company Cassava Sciences achieved?

Cassava Sciences Inc, a leading biopharmaceutical company, has successfully achieved several significant milestones. One notable accomplishment is the development of PTI-125, a novel drug candidate for the treatment of Alzheimer's disease. Cassava Sciences Inc has also undertaken successful clinical trials, demonstrating promising results in improving cognitive function and reducing disease-related biomarkers in patients with Alzheimer's. Additionally, the company secured FDA's Fast Track designation for PTI-125, highlighting its potential as a breakthrough therapy. Cassava Sciences Inc's dedication to advancing innovative treatments for neurodegenerative diseases has positioned them as a front-runner in the pharmaceutical industry.

What is the history and background of the company Cassava Sciences?

Cassava Sciences Inc, founded in 1998, is a biopharmaceutical company focused on the development of innovative drugs for the treatment of Alzheimer's disease. The company's mission is to provide hope to patients and their families by advancing scientific research and clinical trials. Cassava Sciences Inc has dedicated years of research to elucidate the underlying causes of Alzheimer's disease and develop an effective treatment approach. With a strong emphasis on innovation and collaboration, the company has made significant strides in advancing their drug candidate, PTI-125, through clinical trials. Cassava Sciences Inc's commitment to addressing this critical unmet medical need has positioned the company as a leader in the Alzheimer's research field.

Who are the main competitors of Cassava Sciences in the market?

Some of the main competitors of Cassava Sciences Inc in the market include Biogen Inc, Eli Lilly and Company, and Roche Holding AG.

In which industries is Cassava Sciences primarily active?

Cassava Sciences Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Cassava Sciences?

The business model of Cassava Sciences Inc revolves around the development of innovative drugs to address neurodegenerative diseases, with a particular focus on Alzheimer's disease. The company utilizes its proprietary technology and scientific expertise to identify and develop small molecule drug candidates that target the abnormal accumulation of tau proteins in the brain, a hallmark feature of Alzheimer's disease. Through rigorous research and clinical trials, Cassava Sciences aims to bring safe and effective treatments to patients, ultimately improving their quality of life.

What is the P/E ratio of Cassava Sciences 2024?

The Cassava Sciences P/E ratio is -13.54.

What is the P/S ratio of Cassava Sciences 2024?

The Cassava Sciences P/S ratio is 0.

What is the AlleAktien quality score of Cassava Sciences?

The AlleAktien quality score for Cassava Sciences is 2/10.

What is the revenue of Cassava Sciences 2024?

The revenue cannot currently be calculated for Cassava Sciences.

How high is the profit of Cassava Sciences 2024?

The expected Cassava Sciences profit is -38.17 M USD.

What is the business model of Cassava Sciences

Cassava Sciences Inc is a biopharmaceutical company focused on the development of therapies for neurodegenerative diseases. The company is working on the development of drugs for the treatment of Alzheimer's disease, which is one of the most common neurodegenerative diseases. The company's business model is based on the development of novel drugs to improve the memory and cognitive function of patients with Alzheimer's disease. Cassava Sciences Inc has a comprehensive understanding of the pathophysiology of the disease and is working on the identification of compounds that can slow down the progression of the disease. One of the company's key products is the drug candidate PTI-125, which is currently being tested in phase 2 studies. PTI-125 is a peptide molecule that reduces amyloid breakdown and neuroinflammation in the brain. The use of PTI-125 is expected to contribute to the improvement of cognitive function in patients with Alzheimer's. Cassava Sciences Inc also has a pipeline of drug candidates, including PTI-125, PTI-125D, and PTI-333. These drug candidates target various aspects of Alzheimer's disease, including amyloid reduction, tau reduction, and inflammation inhibition. The company also uses a licensing model to fund its research and development. In 2018, the Japanese company Takeda acquired an exclusive license to develop and market PTI-125 in Japan. Cassava Sciences Inc received an upfront payment of $30 million, as well as future milestone payments and licensing fees. Additionally, Cassava Sciences Inc has a comprehensive intellectual property portfolio in the field of Alzheimer's therapy. The company has filed 16 patents and owns 7 granted patents in the US and Europe. Cassava Sciences Inc collaborates with leading academic institutions and research facilities to accelerate the research and development of its drug candidates. The company also has its own clinical department to evaluate its drug candidates in clinical trials. In summary, Cassava Sciences Inc's business model is focused on developing novel therapies to improve the memory and cognitive function of patients with Alzheimer's disease. The company has a strong pipeline of drug candidates and uses a licensing model to fund its research and development. Collaboration with leading academic institutions and research facilities, as well as protection of intellectual property, are important elements of Cassava Sciences Inc's business model.

What is the Cassava Sciences dividend?

Cassava Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does Cassava Sciences pay dividends?

The dividend cannot currently be calculated for Cassava Sciences or the company does not pay out a dividend.

What is the Cassava Sciences ISIN?

The ISIN of Cassava Sciences is US14817C1071.

What is the Cassava Sciences WKN?

The WKN of Cassava Sciences is A2PGL8.

What is the Cassava Sciences ticker?

The ticker of Cassava Sciences is SAVA.

How much dividend does Cassava Sciences pay?

Over the past 12 months, Cassava Sciences paid a dividend of 5.25 USD . This corresponds to a dividend yield of about 42.58 %. For the coming 12 months, Cassava Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Cassava Sciences?

The current dividend yield of Cassava Sciences is 42.58 %.

When does Cassava Sciences pay dividends?

Cassava Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cassava Sciences?

Cassava Sciences paid dividends every year for the past 0 years.

What is the dividend of Cassava Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cassava Sciences located?

Cassava Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cassava Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cassava Sciences from 12/24/2012 amounting to 0.75 USD, you needed to have the stock in your portfolio before the ex-date on 12/13/2012.

When did Cassava Sciences pay the last dividend?

The last dividend was paid out on 12/24/2012.

What was the dividend of Cassava Sciences in the year 2023?

In the year 2023, Cassava Sciences distributed 0 USD as dividends.

In which currency does Cassava Sciences pay out the dividend?

The dividends of Cassava Sciences are distributed in USD.

All fundamentals about Cassava Sciences

Our stock analysis for Cassava Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cassava Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.